idelalisib
Selected indexed studies
- Idelalisib. (, 2012) [PMID:31644147]
- Idelalisib. (Recent Results Cancer Res, 2018) [PMID:30069634]
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). (J Clin Oncol, 2025) [PMID:40479620]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Idelalisib. (2012) pubmed
- Idelalisib. (2018) pubmed
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). (2025) pubmed
- Idelalisib. (2016) pubmed
- Idelalisib. (2006) pubmed
- Idelalisib in the management of lymphoma. (2016) pubmed
- Idelalisib: first global approval. (2014) pubmed
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2020) pubmed
- Idelalisib for the treatment of non-Hodgkin lymphoma. (2016) pubmed
- PMID:40953164 (2019) pubmed